Paul Swiecicki, M.D.
Dr. Swiecicki attended undergrad at Michigan State University where he obtained degrees in human biology as well as physiology, after which he continued his education at the Michigan State College of Human Medicine. He did his internal medicine residency at the Mayo Clinic in Rochester, MN, after which he did his Hematology/Oncology fellowship at the University of Michigan where his research interests pivoted to head and neck cancer. After fellowship, he remained on staff and is currently a clinical associate professor in the Division of Hematology/Oncology at the University of Michigan where his clinical and research interests are primarily in head and neck cancer and early-stage therapeutics. He is co-director of the Experimental Therapeutics/Phase 1 Research Team as well as Associate Director of the University of Michigan Oncology Clinical Trial Support Unit. He has participated in development of ASTRO and ASCO guidelines for topics in Head and Neck Cancer and is the co-PI of S2101/iMATCH pilot trial evaluating Cabozantinib and Nivolumab in patients with advanced solid tumors stratified by tumor biomarkers).
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Remix TherapeuticsTopic:Advisory Board- Salivary Gland CancerDate added:04/15/2024Date updated:04/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Elevar TherapeuticsTopic:Advisory Board- Salivary Gland CancerDate added:04/15/2024Date updated:04/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:CDR LifeTopic:Advisory Board- HN CancerDate added:04/15/2024Date updated:04/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstellasTopic:Advisory Board- HN CancerDate added:04/15/2024Date updated:04/15/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:RegeneronTopic:Advisory Board- HN CancerDate added:04/15/2024Date updated:04/15/2024